The integrated analysis establishes the first cross-species model for GNB1E, suggests common neurological mechanisms and molecular pathways linked to GNB1E, and provides a framework for mechanistic and therapeutic studies.
The findings implicate DCLK1 in a previously unrecognized progressive neurodevelopmental disorder and demonstrate the power of integrative cross-species functional genomics in resolving ultra-rare disease variants.
Stephen C. Pak, David Butler, Wei-Xi Yuan et al.· Research Square· 0 citations
GNB1 encephalopathy (GNB1-E) is a rare neurodevelopmental disorder associated with motor dysfunction, epilepsy and learning disability caused by mutations in the gene encoding the G protein subunit Gβ1. Previous work has shown that altered Gβ1 can disrupt activation of G-protein-coupled inwardly rectifying potassium (GIRK) channels, dysregulate neuronal excitability and cause seizures. However, the relevant upstream regulators of Gβ1 and the consequences of GIRK dysfunction for neuronal synaptic, cellular and circuit function have not been characterized. Here we report that mice of both sexes carrying the deleterious p.I80T mutation in Gnb1 present features consistent with GNB1-E, including developmental delay, decreased locomotion and increased anxiety. Using histology, whole-cell patch-clamp electrophysiology and pharmacology in ex vivo brain slices, we find that hippocampal neurons in heterozygous Gnb1I80T/+ mice exhibit simplified dendritic morphologies, decreased synaptic inhibition mediated by metabotropic GABAB receptors and increased dendritic excitability. These phenotypes result in longer duration dendritic calcium spikes in response to synaptic afferent stimulation, an effect that is reversed by a specific activator of GIRK channels, ML297. Given the known roles of dendritic calcium spikes in driving burst firing and inducing synaptic plasticity, these findings suggest that targeting dendritic excitability has therapeutic potential to address both the seizure susceptibility and learning deficits associated with GNB1-E. Significance Statement GNB1 encephalopathy (GNB1-E) is a rare neurodevelopmental disorder associated with motor dysfunction, epilepsy and learning disability for which there are currently no mechanism-based treatments. Here we show that a pathogenic variant of the G protein subunit Gβ1 impairs activation of neuronal G-protein-coupled inwardly rectifying potassium (GIRK) channels by inhibitory synaptic GABAB receptors. This leads to increased dendritic excitability and longer duration dendritic calcium spikes in mouse hippocampal neurons in response to stimulation of synaptic inputs. We find that this phenotype is reversed by a drug that activates GIRK channels, opening pathways to develop therapies for GNB1-E that specifically target dendritic excitability.
Sam Gritz, Anshul Voleti, Matthew S. Scarnati et al.· bioRxiv· 0 citations
A comprehensive narrative review of studies indexed in PubMed/MEDLINE, Embase, Cochrane Library, ClinicalTrials.gov, and American Epilepsy Society proceedings through January 2026 positions STXBP1-RD as a leading test case for precision medicine in DEEs.
In two patients with SCN2A epileptic encephalopathy, treatment with personalized allele-selective antisense oligonucleotides led to a decrease in seizure frequency with a positive safety profile, and a pathway from n = 1 to n of more patients with SCN2A-RD and other monogenic disorders is provided.
Olivia Kim-Mcmanus, L. Mignon, J. Douville et al.· Nature Medicine· 2 citations
This study represents the first application of a Drosophila model to demonstrate that KCNK3 functions as a dosage-sensitive regulator of neurodevelopment and position KCNK3 as a candidate gene for molecular screening and pave the way for future functional studies and therapeutic exploration in NDDs.
OBJECTIVE
SCN2A pathogenic mutations, such as the recurrent heterozygous Nav1.2-L1342P, are monogenic causes of epilepsy. In this human-induced pluripotent stem cell-derived model system, we aim to investigate the molecular and cellular mechanisms underlying SCN2A-L1342P-associated pathology.
METHODS
Using a human male induced pluripotent stem cell (iPSC) reference line (KOLF) carrying the Nav1.2-L1342P mutation, we generated three-dimensional (3D) cortical organoids for functional studies. Patch-clamp, multi-electrode array (MEA) recordings, immunocytochemistry, and RNA sequencing were used to characterize the disease phenotypes.
RESULTS
Nav1.2-L1342P organoid neurons displayed increased intrinsic excitability and amplified excitatory post-synaptic currents, which are consistent with an increase in excitatory synapse formation revealed by SYN1/PSD95 immunostaining. Moreover, elevated network firing activity, as demonstrated by MEA, indicates a pronounced network hyperexcitability. Transcriptomic profiling of organoids carrying the Nav1.2-L1342P mutation further revealed significant alterations in synaptic, glutamatergic, developmental, and senescence/apoptotic pathways.
SIGNIFICANCE
Our findings demonstrate that the Nav1.2-L1342P mutation drives a multifaceted disease phenotype, including network hyperexcitability and disruption of pathways related to neuronal and synaptic functions. These results advance our understanding of SCN2A-related developmental and epileptic encephalopathy (DEE), laying a foundation for personalized interventions.
M. I. Olivero-Acosta, Morgan Robinson, Zhefu Que et al.· Epilepsia· 0 citations